Recent advances in developing specific therapies for haemophilia

Area of Science:

• Hematology
• Pharmacology
• Biotechnology

Background:

• Haemophilia treatment traditionally relies on replacement therapy with factors VIII or IX.
• A key limitation of current therapies is the short half-life of clotting factors, necessitating frequent infusions.

Purpose of the Study:

• To review recent significant advancements in haemophilia therapy.
• To highlight novel treatment strategies and their potential impact on patient care.

Main Methods:

• Review of recent literature on haemophilia therapeutics.
• Analysis of novel treatment modalities including extended half-life factors, bispecific antibodies, and gene therapy.

Main Results:

• Half-lives of factors VIII and IX have been extended using various moieties, enabling less frequent infusions.
• Novel treatments include a bispecific antibody mimicking factor VIII and strategies inhibiting antithrombin synthesis for haemostatic rebalancing.
• These novel treatments are administered subcutaneously, at infrequent intervals, and are effective in patients with inhibitors.
• Gene therapy shows preliminary success for haemophilia A and B, suggesting a potential cure.

Conclusions:

• Haemophilia therapy has rapidly evolved, offering improved treatment options.
• Novel approaches provide less frequent administration and efficacy in complex patient populations.
• Gene therapy represents a promising avenue towards a potential cure for haemophilia.